Treatment of Indolent or Smoldering Systemic Mastocytosis with Recurrent Hypotension
Patients with indolent or smoldering systemic mastocytosis (ISM/SSM) who experience recurrent hypotension represent a subset requiring targeted symptom management. Clinical goals in this population centre on anaphylaxis prevention, symptom control, and addressing related complications.
Clinical scenario
Indolent or smoldering systemic mastocytosis with recurrent hypotension. Treatment goals are primarily directed toward anaphylaxis prevention, symptom control, and osteoporosis management.
Treatment approach — partial overview
The structured protocol for this scenario includes corticosteroid therapy as a component of management for recurrent hypotensive episodes.
Full eligibility criteria, sequencing, and complete regimen details available in the structured protocol →
References
DOI: 10.1002/ajh.26962
- Treatment goals for ISM patients are primarily directed toward anaphylaxis prevention/symptom control/osteoporosis treatment.
- Prednisone (as above)
View source ↗